Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERASE: Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation
NCT05554419Phase 2Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2027
- Primary completion
- Dec 2030
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of venetoclax, daunorubicin + cytarabine liposome, azacitidine in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
venetoclaxdaunorubicin + cytarabine liposomeazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05554419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05554419.